Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Delcath Systems, Inc. develops interventional oncology products targeting primary and metastatic liver cancers. Its core offerings include the HEPZATO KIT and CHEMOSAT systems for liver-directed chemotherapy delivery. The company serves patients with liver metastases from cancers such as uveal melanoma, colorectal, breast, and neuroendocrine tumors. It focuses on clinical development, regulatory approval, and commercialization of innovative treatments to address significant unmet medical needs in oncology.
This description was generated via AI from an annual report. Updated about 1 year ago.